NKGen Biotech, Inc.

Graf Acquisition Corp. IV, trading under the ticker GFOR, is a blank-check company sponsored by Graf & Company, the serial SPAC sponsor led by James Graf, which completed its initial public offering in 2021 targeting the healthcare and biotechnology sector. The SPAC announced a business combination with NKGen Biotech, Inc., a clinical-stage natural killer cell immunotherapy company focused on oncology and neurological disease, with NKGen filing a quarterly report on Form 10-Q under the GFOR ticker in November 2022 as the de-SPAC transaction progressed. The filing reflects the combined entity's transitional reporting obligations ahead of the deal's close. Sign up for full data, filings, and deal timelines on SpacDesk.